What is Theravance Biopharma 12-1 Month Momentum %?
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-29), Theravance Biopharma's 12-1 Month Momentum % is -20.47%.
The industry rank for Theravance Biopharma's 12-1 Month Momentum % or its related term are showing as below:
TBPH's 12-1 Month Momentum % is ranked better than 50.34% of 1478
companies
in the Biotechnology industry
Industry Median: -20.775
vs TBPH: -20.47
Competitive Comparison of Theravance Biopharma's 12-1 Month Momentum %
For the Biotechnology subindustry, Theravance Biopharma's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Theravance Biopharma 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Theravance Biopharma's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Theravance Biopharma (Theravance Biopharma) Business Description
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TBPH has been successfully added to your